Showing results (31-40 of 47) with videos related to
Sort By:
Pageof 5
The Journal of Laboratory and Clinical Medicine|February 6, 1998
Temporal induction of clusterin in the peri-infarct zone after experimental myocardial infarction in the ratJ R Silkensen, A T Hirsch, M M Lunzer, et al.ACS Chemical Neuroscience|August 22, 2020
Comparative Intracerebroventricular and Intrathecal Administration of a Nanomolar Macrocyclic Melanocortin Receptor Agonist MDE6-5-2c (c[Pro-His-DPhe-Arg-Trp-Dap-Ala-DPro]) Decreases Food Intake in MiceDanielle N Adank, Mary M Lunzer, Mark D Ericson, et al.Proceedings of the National Academy of Sciences of the United States of America|June 4, 2005
A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimersMaria Waldhoer, Jamie Fong, Robert M Jones, et al.ACS Chemical Neuroscience|January 25, 2018
Structure-Activity Relationship Studies of a Macrocyclic AGRP-Mimetic Scaffold c[Pro-Arg-Phe-Phe-Asn-Ala-Phe-DPro] Yield Potent and Selective Melanocortin-4 Receptor Antagonists and Melanocortin-5 Receptor Inverse Agonists That Increase Food Intake in MiceKatlyn A Fleming, Mark D Ericson, Katie T Freeman, et al.Journal of Medicinal Chemistry|December 31, 2008
Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligandsYaguo Zheng, Eyup Akgün, Kaleeckal G Harikumar, et al.Neuropharmacology|April 11, 2019
The bivalent ligand MCC22 potently attenuates hyperalgesia in a mouse model of cisplatin-evoked neuropathic pain without tolerance or rewardGiuseppe Cataldo, Samuel J Erb, Mary M Lunzer, et al.Proceedings of the National Academy of Sciences of the United States of America|March 10, 2011
N-naphthoyl-beta-naltrexamine (NNTA), a highly selective and potent activator of μ/kappa-opioid heteromersAjay S Yekkirala, Mary M Lunzer, Christopher R McCurdy, et al.Journal of Medicinal Chemistry|July 1, 2014
Putative kappa opioid heteromers as targets for developing analgesics free of adverse effectsMorgan Le Naour, Mary M Lunzer, Michael D Powers, et al.Neuropharmacology|July 5, 2019
Targeting MOR-mGluR<sub>5</sub> heteromers reduces bone cancer pain by activating MOR and inhibiting mGluR5Sarah S Shueb, Samuel J Erb, Mary M Lunzer, et al.Biochemistry|September 15, 2020
FBNTI, a DOR-Selective Antagonist That Allosterically Activates MOR within a MOR-DOR HeteromerEyup Akgün, Mary M Lunzer, Defeng Tian, et al.Pageof 5